Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-354 at Kappa Opioid and Mu Opioid Receptors in Brain Following Single Oral Doses in Healthy Participants Using Positron Emission Tomography

NCT05547542 is registered in ClinicalTrials.gov with Cerevel Therapeutics, LLC as lead sponsor.

NCT NCT05547542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05547542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-354 at Kappa Opioid and Mu Opioid Receptors in Brain Following Single Oral Doses in Healthy Participants Using Positron Emission Tomography
Lead sponsor
Cerevel Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
March 2, 2023
Completion date
August 6, 2024
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder